指南与共识免疫规划卫生政策与健康促进

美国成人使用15价肺炎球菌结合疫苗和20价肺炎球菌结合疫苗:免疫实践咨询委员会更新建议——美国,2022年

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2022-01-28

2021年FDA批准PCV20和PCV15用于≥18岁成人,基于与PCV13及PPSV23的抗体应答比较研究。2021年10月20日ACIP推荐≥65岁成人及19-64岁有特定基础疾病或风险因素且未接种过PCV或接种史不详者使用PCV20单剂或PCV15序贯PPSV23。ACIP采用EtR框架和GRADE方法。

要点

  • ACIP推荐≥65岁成人及19-64岁有特定风险且未接种PCV或接种史不详者使用PCV20单剂或PCV15序贯PPSV23。
  • PCV15和PCV20的批准基于与PCV13及PPSV23的抗体应答比较研究。
  • 新推荐简化了此前按年龄和风险分组的PCV13和PPSV23接种建议。

核心结论

  • ACIP推荐≥65岁成人及19-64岁有特定基础疾病或风险因素且未接种过PCV或接种史不详者使用PCV20单剂或PCV15序贯PPSV23。

研究设计与样本

  • ACIP采用Evidence to Recommendation(EtR)框架,使用GRADE方法指导关于这些疫苗使用的审议。

主要发现

  • 2021年FDA批准PCV20和PCV15用于≥18岁成人,基于与PCV13的抗体应答比较研究。
  • PCV15新增2种血清型的抗体应答与PCV13接种后相应应答比较。
  • PCV20新增7种血清型的抗体应答与PPSV23相应应答比较。

关键数值与推荐

  • ACIP推荐≥65岁成人使用PCV20单剂或PCV15序贯PPSV23。
  • ACIP推荐19-64岁有特定基础疾病或风险因素且未接种过PCV或接种史不详者使用PCV20单剂或PCV15序贯PPSV23。

临床怎么用

  • ≥65岁成人及19-64岁有特定风险且未接种PCV或接种史不详者可按ACIP推荐接种PCV20单剂或PCV15序贯PPSV23。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years, based on studies that compared antibody responses to PCV20 and PCV15 with those to 13-valent PCV (PCV13) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.). Antibody responses to two additional serotypes included in PCV15 were compared to corresponding responses after PCV13 vaccination, and antibody responses to seven additional serotypes included in PCV20 were compared with those to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) (Merck Sharp & Dohme Corp.). On October 20, 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years, and for adults aged 19-64 years with certain underlying medical conditions or other risk factors* who have not previously received a PCV or whose previous vaccination history is unknown. ACIP employed the Evidence to Recommendation (EtR) framework,† using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)§ approach to guide its deliberations regarding use of these vaccines. Before this, PCV13 and PPSV23 were recommended for use for U.S. adults and the recommendations varied by age and risk groups. This was simplified in the new recommendations.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085226. doi:10.15585/mmwr.mm7104a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。